Windtree Therapeutics announced it has successfully completed enrollment in its SEISMiC Extension Phase 2b study of istaroxime in early cardiogenic shock caused by heart failure. The study is evaluating the ability of istaroxime to improve heart function and low blood pressure in the setting of early cardiogenic shock due to heart failure. The Company is looking to extend the positive results on these parameters as observed in the Company’s first SEISMiC Phase 2 clinical study that was previously reported. In addition, the Company hopes that the study results will substantiate the encouraging observations from the Company’s Phase 2 clinical study, indicating istaroxime has a favorable renal profile and does not increase cardiac arrhythmias.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WINT:
- Windtree Therapeutics files to sell 26.67M shares of common stock for holders
- Windtree Therapeutics Reports Second Quarter 2024 Financial Results and Provides Key Business Updates
- Windtree Therapeutics reports Q2 EPS ($20.91) vs. ($29.47) last year
- Windtree Therapeutics Board Reshuffles, Appoints New Directors
- Windtree Announces New Additions and Changes to Its Board of Directors